VIDEO: Concomitant tafamidis, acoramidis use does not alter any ATTRibute-CM endpoints
Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis use in conjunction with acoramidis use did not alter the primary efficacy endpoints of the ATTRibute-CM study.
Daniel P. Judge, MD, professor of medicine at the Medical University of South Carolina, noted that, compared with placebo, concomitant tafamidis (Vyndamax, Pfizer) and acoramidis (Attruby, BridgeBio) use did not impact the four-step primary efficacy endpoint of ATTRibute-CM, including all-cause mortality, CV-related hospitalization, change in N-terminal pro-B-type natriuretic peptide and 6-minute walk distance.
“The ATTRibute-CM clinical trial clearly showed benefits of acoramidis, and it wasn’t altered by the presence of tafamidis,” Judge told Healio.
Reference:
- Judge DP, et al. Primary endpoint efficacy results in the ATTRibute-CM study: Prespecified sensitivity analyses addressed tafamidis use. Presented at: American College of Cardiology Scientific Session; March 29-31, 2025; Chicago (hybrid meeting).
Collapse
Healio Interviews
Read more about